Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.35 |
| ▸ | MEN1 | O00255 | 12/20 | 0.35 |
| ▸ | MAPT | P10636 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | APAF1 | O14727 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18203882 | 0.70 | MEN1 (0.52) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4074645 | 0.68 | GAA (0.34) | MAPTGAA | |
| SCHEMBL1005829 | 0.67 | ALDH1A1 (0.45) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL3944442 | 0.65 | GRK6 (0.39) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL29413773 | 0.64 | GRK6 (0.42) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL29988480 | 0.64 | GRK6 (0.42) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL8113 | 0.64 | GRK6 (0.42) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL11423023 | 0.62 | GRK6 (0.41) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL752653 | 0.62 | GRK6 (0.37) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL2865 | 0.62 | ALDH1A1 (0.39) | KMT2AMEN1MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153605-B1 | METHOD FOR PRODUCING A LAYERED (SEMI-)CONDUCTIVE MATERIAL | UNIV DRESDEN TECH (DE) | 2018-07-11 | — | — | EP | claimed |
| EP-3153605-A1 | METHOD FOR PRODUCING A LAYERED (SEMI-)CONDUCTIVE MATERIAL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-04-12 | — | — | EP | claimed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | claimed |
| US-8652752-B2 | Sulphonium salt initiators | BASF SE (DE) | 2014-02-18 | — | — | US | claimed |
| EP-2197840-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-11-06 | — | — | EP | claimed |
| US-8034941-B2 | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20100297540-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-11-25 | — | — | US | claimed |
| EP-2197872-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Novartis Ag (CH) | 2010-06-23 | — | — | EP | claimed |
| EP-2197869-A1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2010-06-23 | — | — | EP | claimed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| WO-2009047105-A1 | SULPHONIUM SALT INITIATORS | BASF SE (CH) | 2009-04-16 | — | — | WO | claimed |
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | BEERLI RENE | 2009-03-19 | — | — | US | claimed |
| WO-2009027475-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | NOVARTIS AG (CH) | 2009-03-05 | — | — | WO | claimed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | claimed |
| CN-101346370-A | PDF inhibitors | NOVARTIS AG (CH) | 2009-01-14 | — | — | CN | claimed |
| EP-1973898-A1 | PDF INHIBITORS | Novartis AG (CH) | 2008-10-01 | — | — | EP | claimed |
| EP-1641799-B1 | IMIDAZO-PYRIDAZINONE DERIVATIVES AND IMIDAZO-PYRIDONE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-03-12 | — | — | EP | claimed |
| WO-2007077186-A1 | PDF INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | claimed |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | RAD52 4803/4885KMT2A 3970/4885MEN1 3475/4885 |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | RAD52 4623/4885KMT2A 3711/4885MEN1 3546/4885 |
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | CAMK1D, CAMK1, PHPT1 | RAD52 3537/4885KMT2A 2295/4885MEN1 1835/4885 |
| US-20100297540-A1 | SULPHONIUM SALT INITIATORS | SULT1A1, SULT2A1, NCOA1 | RAD52 4561/4885KMT2A 320/4885MEN1 4604/4885 |
| US-20050026921-A1 | New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | RAD52 4527/4885KMT2A 2813/4885MEN1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.